Patients with Leber hereditary optic neuropathy treated with Lumevoq experienced sustained efficacy and safety after 2 years as part of the phase 3 REFLECT clinical trial, according to a press release from GenSight Biologics.
REFLECT is a special protocol assessment-designed, randomized, double-masked, placebo-controlled trial investigating Lumevoq (GS010; lenadogene nolparvovec) in 98 patients with vision loss due to Leber hereditary optic neuropathy (LHON). All patients received Lumevoq in the first affected eye and were then randomly assigned to receive either Lumevoq or placebo injection